Search Results for "Ema Has Approuved Prevnar 13 Vaccine For Adults"
Matching Channels
Streptococcal streptococcus pneumoniae vaccine
Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-p...
Screening and diagnosis of children and adults
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt typ...
Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella-zoster virus is known by many names, including: chickenpox virus, varicella viru...
Matching News
Pfizer: Prevnar 13 Effective in Young Adults
(MedPage Today) -- The 13-valent pneumococcal polysaccharide conjugate vaccine (Prevnar 13) elicits as strong an immune response in adults 18 to 49 as it does in those ages 60 to 64, according to phas...
FDA clears expanded use of Pfizer pneumococcal conjugate vaccine Prevnar 13
Pfizer has obtained FDA approval for the expanded use of Prevnar 13, pneumococcal conjugate vaccine, in children and adults between six to 17 years of age who are new to the vaccine.
Pfizer unveil results of Prevnar 13 in adults with HIV phase 3 study
Pfizer have unveiled the results from a Phase 3 study that trialled pneumococcal vaccine Prevnar 13 in adults infected with human immunodeficiency virus (HIV). In [...]
Pfizer's Prevnar 13: The World's Leading Vaccine And Its Competitors
By Peter Geschek:Prevnar 13 from Pfizer's (PFE) Wyeth division is an enormously successful pneumococcal conjugate vaccine, currently the best-selling vaccine in the world. Prevnar 13 was first introdu...
Pfizer unveil results of Prevnar 13 Phase 3 study in adults with HIV
Pfizer have unveiled the results from a Phase 3 study that trialled pneumococcal vaccine Prevnar 13 in adults infected with human immunodeficiency virus (HIV). In [...]
Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And ...
Prevnar 13 is the First and Only Pneumococcal Conjugate Vaccine Approved for This Age Group
Pfizer gets broader Prevnar 13 vaccine approval
Pfizer Inc. said Tuesday that European Union regulators approved the use of its Prevnar 13 vaccine in children and adolescents aged 6 to 17.The vaccine protects against 13 strains of pneumococcal bac...
ACIP: High-Risk Adults Need Two Pneumoncoccal Vaccines
ATLANTA (MedPage Today) -- Adults with immunocompromising conditions should receive pneumococcal conjugate vaccine (Prevnar 13, PCV13) in addition to the 23-serotype polysaccharide vaccine (Pneumovax...
Matching PubMed Articles
The incidence of invasive pneumococcal disease (IPD), caused by the approximately 91 serotypes of Streptococcus pneumoniae (PN), varies geographically and temporally as a result of changing epidemiolo...
An expanded pneumococcal vaccine (prevnar 13) for infants and children.
On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidi...
Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
In 2010, 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.]) was licensed by the Food and Drug Administration (FDA) and recommended...
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13; Prevenar 13(®); Prevnar 13(®)) is approved in adults aged ≥50 years (focus of review) and in children aged 6 weeks to...
